



International Journal of

Innovative Drug Discovery

www.ijidd.com

 e ISSN 2249 - 7609
 Print ISSN 2249 - 7617

NANOMEDICINE IN PHARMACOLOGY APPLICATIONS IN DIAGNOSIS AND DRUG DELIVERY – A REVIEW ARTICLE.

Mageshwaran S^{1*}, Dr. Kalvimoorthi V², Gopi L³

¹M.Pharm, First Year, Pharmacology, Aadhi Bhagawan College Of Pharmacy, Rantham, Thiruvannmalai, Tamil Nadu, India.

²Professor, Cum HOD Department Of Pharmaceutics, Aadhi Bhagawan College Of Pharmacy, Rantham, Thiruvannmalai, Tamil Nadu, India.

³Assistant Professor, Department Of Pharmaceutics, Aadhi Bhagawan College Of Pharmacy, Rantham, Thiruvannmalai, Tamil Nadu, India.

ABSTRACT

Nanomedicine brings nanotechnology and Medicine together in order to develop novel therapies and improve existing treatments. In nanomedicine, atoms and molecules are manipulated to produce nanostructures of the same size as biomolecules for interaction with human cells. This procedure offers a range of new solutions for diagnoses and "smart" treatments by stimulating the body's own repair mechanisms.

KEY WORDS: Nanomedicine, Nanoparticles, Drug Delivery, Targeted Therapy.

INTRODUCTION

Nanomedicine refers to the application of nanotechnology in healthcare for disease prevention, diagnosis, and treatment. Nanotechnology involves the manipulation of materials at the nanoscale (1–100 nm), where unique physical, chemical, and biological properties emerge. The integration of nanotechnology into pharmacology has revolutionized drug development by enabling site-specific delivery, improved pharmacokinetics, enhanced drug stability, and reduced adverse effects.

Traditional drug delivery systems often suffer from poor solubility, low bioavailability, rapid degradation, non-specific distribution, and significant side effects. Nanomedicine addresses these limitations through engineered nanocarriers capable of transporting therapeutic agents directly to target tissues.

Nano pharmacology

Nano pharmacology is a relatively newer branch of pharmacology which investigates interaction of a nanomedicine with living systems at the nanoscale level. It focusing on surface-modified nanocarriers and their therapeutic potential for targeted drug delivery.

Fundamentals of Nanomedicine:

Nanomedicine utilizes nanoscale materials for therapeutic and diagnostic purposes. These materials possess:

- High surface area
- Enhanced reactivity
- Controlled drug release capabilities
- Improved permeability
- Targeted tissue accumulation
- Functional surface modification

Major goals include:

- Early disease detection
- Targeted drug delivery
- Controlled drug release
- Reduction of drug toxicity
- Personalized medicine
- Combined diagnosis and therapy (theranostics)

Types of Nanoparticles Used in Pharmacology:

Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers.

Advantages

- Biocompatibility
- Ability to carry hydrophilic and hydrophobic drugs
- Reduced toxicity
- Controlled release

Applications

- Cancer chemotherapy
- Vaccine delivery
- Gene therapy

Examples:

- Doxil(liposomal doxorubicin)
- AmBisome(liposomal amphotericin B)

Pharmacologically Some Important Nano Technology Based Drug Delivery

- Polymeric Nanoparticles for Targeted Drug Delivery
- Solid Lipid Nanoparticles in Oral Drug Delivery
- Nanocarriers for Controlled Drug Release
- Dendrimer-Based Drug Delivery Systems
- Nanoparticle-Mediated Brain Drug Delivery Across the Blood-Brain Barrier
- Nanomedicine for Gene Delivery and Gene Therapy
- Nanotechnology-Based Vaccine Delivery Systems
- Stimuli-Responsive Nanocarriers for Precision Drug Delivery
- Nanoparticle Drug Delivery in Personalized Medicine

Diagnostic Applications

- Nanotechnology in Early Cancer Diagnosis
- Nanoparticle-Based Biosensors for Disease Detection
- Gold Nanoparticles in Medical Imaging
- Magnetic Nanoparticles for MRI Contrast Enhancement
- Quantum Dots in Molecular Diagnostics
- Nanomedicine for Infectious Disease Detection
- Nanobiosensors for Point-of-Care Diagnostics
- Nanotechnology in COVID-19 Diagnosis and Monitoring
- Nanoparticle-Assisted Biomarker Detection
- Theranostic Nanoparticles for Simultaneous Diagnosis and Treatment

Cancer Nanomedicine

- Nanomedicine Approaches in Breast Cancer Treatment
- Targeted Nanoparticle Therapy for Lung Cancer
- Nanotechnology-Based Chemotherapy Delivery Systems
- Gold Nanoparticles in Cancer Theranostics

- Nanomedicine for Tumor Imaging and Drug Delivery
- Overcoming Multidrug Resistance Using Nanocarriers
- Nanoparticle-Mediated Photothermal Therapy
- Nanomedicine in Precision Oncology
- Recent Advances in Cancer Nanotherapeutics
- Clinical Applications of Nanomedicine in Oncology

Neurological Disorders

- Nanomedicine for Alzheimer's Disease Treatment
- Nanotechnology in Parkinson's Disease Therapy
- Brain-Targeted Nanocarriers for CNS Disorders
- Nanoparticles for Neurodegenerative Disease Diagnosis
- Nanomedicine Strategies for Stroke Management

Infectious Diseases

- Nanomedicine in Antimicrobial Drug Delivery
- Nanoparticles Against Antibiotic Resistance
- Nanotechnology-Based Antiviral Therapies
- Nanomedicine for Tuberculosis Treatment
- Nanocarriers in Vaccine Development

Cardiovascular Applications

- Nanomedicine in Cardiovascular Drug Delivery
- Nanotechnology for Atherosclerosis Diagnosis and Treatment
- Nanoparticles in Cardiac Tissue Regeneration
- Nanomedicine for Hypertension Management
- Targeted Drug Delivery in Cardiovascular Diseases

Emerging Trends

- Artificial Intelligence in Nanomedicine Design
- Smart Nanoparticles for Precision Medicine
- Nanorobotics in Drug Delivery
- Future Perspectives of Nanomedicine in Pharmacology
- Regulatory Challenges and Safety Issues in Nanomedicine
- Toxicological Evaluation of Pharmaceutical Nanoparticles
- Ethical Considerations in Clinical Nanomedicine
- Personalized Nanomedicine and Precision Healthcare
- Nanomedicine in Regenerative Medicine
- Clinical Translation of Nanotechnology-Based Therapeutics

APPLICATIONS**Applications of Nanomedicine in Diagnosis & Drug Delivery**

Molecular Imaging

Nanoparticles enhance imaging sensitivity and specificity.

- **Techniques:** MRI, CT, PET, Fluorescence imaging, Ultrasound imaging.
- **Benefits:** Early disease detection, Improved image contrast, Real-time monitoring.

Cancer Diagnosis:

Nanoparticles can accumulate preferentially in tumor tissues through:

- Enhanced permeability and retention (EPR) effect
- Active targeting using ligands

Applications: Tumor imaging, Biomarker detection, Early-stage diagnosis

Biosensors:

- **Nanotechnology-based biosensors detect:** Proteins, DNA, Pathogens, Biomarkers.
- **Advantages:** High sensitivity, Rapid detection, Point-of-care diagnostics.

Infectious Disease Diagnosis:

- **Nanoparticles have improved diagnostic platforms for:** Tuberculosis, HIV, Influenza, COVID-19
- **Benefits:** Faster results, Greater sensitivity, Portable testing systems

Targeted Drug Delivery:

Targeted delivery minimizes exposure of healthy tissues.

Passive Targeting

Utilizes EPR effect in tumors.

Active Targeting

- **Uses:** Antibodies, Peptides, Aptamers, Receptor ligands.
- **Benefits:** Increased efficacy, Reduced toxicity, Improved patient outcomes.

Controlled Drug Release

- **Nanocarriers enable:** Sustained release, Triggered release, Environment-responsive release.
- **Triggers include:** pH, Temperature, Enzymes, Magnetic fields.
- **Advantages:** Reduced dosing frequency, Better compliance, Improved therapeutic outcomes.

Cancer Therapy:

Cancer remains the most successful application of nanomedicine.

- **Examples:** Liposomal doxorubicin, Paclitaxel nanoparticles, Albumin-bound nanoparticles.

- **Benefits:** Higher tumor accumulation, Reduced cardiotoxicity, Improved survival rates.

Brain Drug Delivery:

The blood-brain barrier limits conventional drug delivery.

- **Nanoparticles facilitate:** BBB penetration, Targeted delivery to neurons, Treatment of neurodegenerative diseases.
- **Applications:** Alzheimer's disease, Parkinson's disease, Brain tumors.

Gene Delivery:

- **Nanocarriers deliver:** DNA, RNA, siRNA, CRISPR systems
- **Advantages:** Protection from degradation, Enhanced cellular uptake, Improved transfection efficiency.

Vaccine Delivery:

- **Nanoparticles improve vaccine performance by:** Protecting antigens, Enhancing immune responses, Enabling controlled release.
- **Applications:** mRNA vaccines, Cancer vaccines, Infectious disease vaccines.

Theranostics

Integration of Diagnosis and Therapy. Theranostics combines diagnosis and treatment in a single nanoparticle platform.

- **Functions:** Disease detection, Drug delivery, Treatment monitoring.
- **Examples:** Magnetic nanoparticles, Gold nanoparticles, Quantum dots.
- **Advantages:** Personalized treatment, Real-time therapeutic monitoring, Improved treatment outcomes



CHALLENGES AND LIMITATIONS:

- Despite promising results, several issues remain:
- Toxicity
- Oxidative stress
- Cellular damage
- Long-term accumulation
- Regulatory Challenges
- Lack of standardized guidelines
- Complex approval processes
- Manufacturing Issues
- Scalability
- Reproducibility
- Cost-effectiveness
- Biological Barriers
- Immune clearance
- Protein corona formation
- Biodistribution variability

Future Perspectives:

Future developments are expected in:

- Personalized nanomedicine
- Artificial intelligence-assisted nanoparticle design
- Smart drug delivery systems
- Nanorobotics
- Precision oncology
- Advanced theranostic platforms
- Emerging technologies may enable highly individualized treatments with superior efficacy and safety profiles.

Figure 1: Liposome.**Figure 2: Future Developments.****DISCUSSION:**

Nanomedicine has emerged as one of the most transformative fields in modern pharmacology by integrating nanotechnology with pharmaceutical sciences to improve disease diagnosis, prevention, and treatment. The nanoscale size (1–100 nm) of engineered drug carriers enables unique physicochemical properties, including enhanced surface area, improved cellular uptake, controlled drug release, and selective tissue targeting. Compared with conventional dosage forms, nanocarriers significantly improve drug solubility, stability, bioavailability, and therapeutic efficacy while minimizing systemic toxicity and adverse effects.

Among various nanocarrier systems, liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, nanomicelles, and metallic nanoparticles have demonstrated remarkable success in targeted drug delivery. Liposomal formulations such as liposomal doxorubicin and amphotericin B have already received clinical approval and have shown superior therapeutic performance with reduced toxicity compared to conventional formulations. Similarly, polymeric nanoparticles and lipid-based carriers provide sustained drug release and prolonged circulation time, making them suitable for chronic disease management.

One of the greatest advantages of nanomedicine is its ability to achieve targeted drug delivery through both

passive and active targeting mechanisms. Passive targeting relies on the enhanced permeability and retention (EPR) effect observed in tumor tissues, whereas active targeting employs ligands, antibodies, peptides, aptamers, or receptor-specific molecules to selectively bind diseased cells. These strategies increase local drug concentration while reducing exposure to healthy tissues, thereby improving treatment outcomes and decreasing adverse drug reactions.

Cancer remains the most extensively investigated application of nanomedicine. Nanoparticle-based chemotherapy has demonstrated improved accumulation of anticancer drugs within tumor tissues, enhanced intracellular uptake, and reduced multidrug resistance. Gold nanoparticles, magnetic nanoparticles, and quantum dots have also expanded the role of nanotechnology in cancer diagnosis through advanced imaging techniques, photothermal therapy, and theranostic applications. These multifunctional platforms simultaneously enable disease detection, drug delivery, and treatment monitoring, representing a significant advancement toward precision oncology.

Recent developments have also highlighted the importance of nanomedicine in neurological disorders. The blood–brain barrier represents a major obstacle for conventional drug delivery systems; however, surface-modified nanoparticles have demonstrated the ability to cross this barrier and deliver therapeutic agents directly into the central nervous system. This approach offers promising therapeutic opportunities for Alzheimer's disease, Parkinson's disease, glioblastoma, epilepsy, and other neurodegenerative disorders.

Nanotechnology has further revolutionized infectious disease management. Lipid nanoparticles played a pivotal role in the successful clinical translation of mRNA vaccines during the COVID-19 pandemic by protecting nucleic acids from degradation and facilitating efficient intracellular delivery. Nanocarriers are also being explored for antimicrobial therapy against multidrug-resistant bacterial infections, tuberculosis, fungal diseases, and viral infections, where conventional therapies often show limited effectiveness.

Diagnostic applications of nanomedicine continue to expand through molecular imaging, biosensors, magnetic resonance imaging, fluorescence imaging, and biomarker detection. Nanoparticle-based biosensors provide rapid, highly sensitive, and point-of-care diagnostic platforms capable of detecting disease biomarkers at very low concentrations. These technologies facilitate earlier diagnosis, continuous monitoring, and personalized therapeutic interventions.

REFERENCES

1. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. *Chem Rev.* 115(19), 2015, 10938-10966.

Despite these significant advances, several challenges continue to limit widespread clinical translation. Nanoparticle toxicity remains an important concern because particle composition, size, surface charge, and biodegradability influence biodistribution, immune responses, oxidative stress, and long-term accumulation within organs. Protein corona formation after systemic administration may alter nanoparticle behavior and reduce targeting efficiency. Furthermore, large-scale manufacturing, batch-to-batch reproducibility, stability during storage, quality control, and regulatory standardization remain major barriers to commercialization. Emerging technologies such as artificial intelligence, machine learning, computational modeling, and nanorobotics are expected to accelerate the design of next-generation nanomedicines. AI-assisted optimization of nanoparticle formulation, prediction of pharmacokinetic behavior, and personalized treatment planning may significantly improve therapeutic success while reducing development costs. In addition, smart stimuli-responsive nanoparticles capable of releasing drugs in response to pH, temperature, enzymes, magnetic fields, or ultrasound are opening new possibilities for precision medicine.

Overall, the current evidence strongly supports nanomedicine as a cornerstone of future pharmacotherapy. Continued interdisciplinary collaboration among pharmaceutical scientists, clinicians, biomedical engineers, toxicologists, and regulatory agencies will be essential to overcome existing limitations and ensure safe, effective, and affordable nanomedicine-based therapies for clinical practice.

CONCLUSION

Nanomedicine has transformed modern pharmacology by providing innovative approaches for disease diagnosis and drug delivery. Nanoparticles improve therapeutic efficacy through targeted delivery, controlled release, enhanced bioavailability, and reduced systemic toxicity. Their applications extend across oncology, neurology, infectious diseases, cardiovascular disorders, and regenerative medicine. Diagnostic advancements, including molecular imaging and biosensors, have enabled earlier and more accurate disease detection. Although challenges related to toxicity, regulation, and large-scale production persist, ongoing research continues to expand the clinical potential of nanomedicine. The future of pharmacology will increasingly rely on nanotechnology-driven therapeutic and diagnostic platforms that support precision medicine and personalized healthcare.

2. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. *Nat Rev Drug Discov.* 20(2), 2021, 101-124.
3. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. *Nat Rev Cancer.* 17(1), 2017, 20-37.
4. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. *Annu Rev Med.* 63, 2012, 185-198.
5. Ventola CL. Progress in nanomedicine: Approved and investigational nanodrugs. *P T.* 42(12), 2017, 742-755.
6. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: A review of FDA-approved materials. *Pharm Res.* 33, 2016, 2373-2387.
7. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. *Nat Nanotechnol.* 2, 2007, 751-760.
8. Ferrari M. Cancer nanotechnology: Opportunities and challenges. *Nat Rev Cancer.* 5, 2005, 161-171.
9. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. *ACS Nano.* 3(1), 2009, 16-20.
10. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers. *Nat Biotechnol.* 33, 2015, 941-951.
11. Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. *Nat Rev Mater.* 1, 2016, 16014.
12. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. *Bioeng Transl Med.* 4(3), 2019, e10143.
13. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. *Nat Rev Mater.* 6, 2021, 1078-1094.
14. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. *Mol Ther.* 25(7), 2017, 1467-1475.
15. Cheng Y, Morshed RA, Auffinger B, et al. Multifunctional nanoparticles for brain drug delivery. *Nat Rev Neurol.* 10, 2014, 615-627.
16. Yetisgin AA, Cetinel S, Zuvun M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted applications. *Molecules.* 25(9), 2020, 2193.
17. He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines. *Nat Nanotechnol.* 14, 2019, 812-818.
18. Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome-assisted drug delivery. *Front Pharmacol.* 6, 2015, 286.
19. Hare JJ, Lammers T, Ashford MB, et al. Challenges and strategies in anti-cancer nanomedicine development. *Adv Drug Deliv Rev.* 108, 2017, 25-38.
20. He Q, Shi J. MSN anti-cancer nanomedicines: Chemotherapy enhancement and overcoming drug resistance. *Adv Mater.* 26(3), 2014, 391-411.